Another step on the road to tailored antiplatelet therapy.
Stephen D
SD
Wiviott
Jessica L
JL
Mega
D054058:Acute Coronary Syndrome / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics; D065731:Cytochrome P-450 CYP2C19; D004247:DNA / Q000235:genetics; D004562:Electrocardiography / Q000187:drug effects; D005838:Genotype; D006801:Humans; D015539:Platelet Activation / Q000187:drug effects* / Q000235:genetics; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011110:Polymorphism, Genetic; D017410:Practice Guidelines as Topic; D016896:Treatment Outcome
D010975:Platelet Aggregation Inhibitors; D004247:DNA; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19